Welcome to our dedicated page for Nls Pharmaceutics news (Ticker: NLSP), a resource for investors and traders seeking the latest updates and insights on Nls Pharmaceutics stock.
NLS Pharmaceutics Ltd (NLSP) delivers cutting-edge therapies for central nervous system disorders through innovative platforms like its dual orexin receptor agonist (DOXA) technology. This page provides essential updates for stakeholders tracking clinical developments, strategic partnerships, and regulatory milestones in neuropharmaceutical research.
Access verified press releases and analysis on NLSP's progress in addressing narcolepsy, neurodegenerative diseases, and cognitive disorders. Our curated news collection covers clinical trial results, intellectual property developments, and financial performance updates critical for informed decision-making.
Key content includes updates on the Kadimastem merger's therapeutic pipeline expansion, DOXA platform validation studies, and collaborative research initiatives. Investors will find timely reports on funding rounds, patent approvals, and preclinical data disclosures.
Bookmark this page for consolidated access to NLSP's latest advancements in CNS therapy development. Regularly updated to reflect material events and scientific breakthroughs, it serves as your primary resource for understanding the company's position in competitive biopharmaceutical markets.
NLS Pharmaceutics Ltd. announces the grant of U.S. Patent No. 11207271 for its lead product candidate, Quilience® (mazindol ER), effective January 4, 2022. This patent covers the use of Quilience® for treating ADHD and narcolepsy, bolstering NLS's intellectual property in key markets including the U.S., Europe, Canada, and South Korea. The company anticipates reporting Phase 2a results for Quilience® in treating narcolepsy in the first quarter of 2022, emphasizing the drug's potential to address significant unmet medical needs.
NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) has released final results from a preclinical study on NLS-4 (Lauflumide), highlighting its potential as a treatment for chronic fatigue associated with Long-Covid. The study indicates that NLS-4 significantly outperformed modafinil in improving circadian rhythm and chronic fatigue syndrome in animal models, at doses four times lower than modafinil. Notably, NLS-4 did not induce weight loss or hepatic toxicity. The company aims to advance NLS-4's development amidst rising demand for effective treatments for Long-Covid fatigue.
NLS Pharmaceutics Ltd. (NASDAQ: NLSP, NLSPW) provides updates in a letter to shareholders from CEO Alex Zwyer, highlighting significant progress in clinical development for Quilience, an innovative narcolepsy treatment. Key achievements include entering Phase 2 clinical trials, successful patent applications in the U.S., Europe, and Canada, and positive pre-clinical data on NLS-4 for chronic fatigue syndrome. The company anticipates reporting interim results from the POLARIS trial in Q1 2022, and plans to explore additional market opportunities for Quilience beyond narcolepsy.
NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) has announced promising preclinical data for its next-generation drug candidate, NLS-4 (Lauflumide), targeting chronic fatigue associated with Long-COVID. In a study, rats treated with NLS-4 exhibited improved nighttime activity and greater motor-stimulating behavior compared to those treated with modafinil. The results suggest NLS-4 may effectively combat symptoms of fatigue and sleep disturbances related to COVID-19. The company is committed to advancing NLS-4 into clinical development to alleviate chronic fatigue in Long-COVID patients.
NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW), a Swiss clinical-stage pharmaceutical company, is set to present at The Micro Cap Rodeo Fall Harvest Conference from October 5-8, 2021. CEO Alex Zwyer will provide a corporate overview on October 5 at 9:00 am ET. The presentation is accessible through a provided link, and a replay will be available on the company's website. NLS's lead candidate, Quilience, is in phase 2 studies for narcolepsy treatment and has received Orphan Drug Designations in the U.S. and Europe.
NLS Pharmaceutics Ltd. (NASDAQ: NLSP, NLSPW) announced a $20 million Standby Equity Distribution Agreement (SEDA) with YA II PN, Ltd., allowing the company to issue common shares over 36 months at an 8% discount. A $2.5 million immediate investment at $1.90 per share is also included. Proceeds will be used for advancing pipeline assets and general working capital. Quilience®, the company's lead product, is in Phase 2 trials for narcolepsy. The shares will only be sold following SEC registration. Risks include potential clinical trial delays and market acceptance issues.
NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) will participate in the Benzinga Healthcare Small Cap Conference on September 29-30, 2021. CEO Alex Zwyer is scheduled for a live interview on September 29 from 1:55 PM to 2:15 PM ET. Attendees can access the interview here, with a replay available on the company website. NLS focuses on developing therapies for rare CNS disorders and is advancing its lead candidate, Quilience, for narcolepsy, which has Orphan Drug Designations in the U.S. and Europe.
NLS Pharmaceutics Ltd. has initiated a Phase 2 clinical trial for its drug Quilience (mazindol ER) targeting excessive daytime sleepiness and cataplexy in narcolepsy patients. Enrolling around 60 patients across 30 centers in the U.S. and Europe, the trial aims to assess its efficacy over 28 days. Primary endpoints include changes in the Epworth Sleepiness Scale and cataplexy attack frequency. Successful completion could lead to significant advancements in treatment options for narcolepsy, addressing an unmet medical need.
NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NASDAQ:NLSPW) announces that CEO Alex Zwyer will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. Investors can access the presentation online starting September 13 at 1:00 PM CET / 7:00 AM ET. This conference includes six industry tracks, highlighting Healthcare & Biotechnology, and offers networking opportunities. NLS is focused on innovative therapies for central nervous system disorders, with its lead candidate, Quilience, targeting narcolepsy and receiving Orphan Drug Designations in the U.S. and Europe.
NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) announced a Notice of Allowance from the USPTO for patent application No. 16/083,131.
This patent will cover oral formulations with immediate-release and sustained-release layers of mazindol for treating attention deficit disorders (ADD, ADHD), narcolepsy, and excessive daytime sleepiness.
The patent is expected to issue in Q4 2021, expiring no earlier than March 2037. NLS aims to include it in the FDA's Orange Book if market approval is obtained.
